1. D-pinitol exerts anti-inflammatory activity.
2. D-Pinitol exerts insulin-like activity, used for many diabetic associated conditions.
3. D-Pinitol is a safe nutrient to reduce calorie consumption when supplementing with creatine.
1. Cannabidiolic acid (CBDA) inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA; it offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers.
2. Cannabidiolic acid displays significantly greater potency at inhibiting vomiting in shrews and nausea in rats, and at enhancing 5-HT(1A) receptor activation, an action that accounts for its ability to attenuate conditioned gaping in rats.
3. Cannabidiolic acid selectively inhibits cyclooxygenase (COX)-2 activity with an IC(50) value around 2 microM, has 9-fold higher selectivity than COX-1 inhibition.
4. Cannabidiolic acid and cannabidiol have inhibitory actions on the intestines of S. murinus that are not neuronallymediated or mediated via CB1 or CB2 receptors.
1. Gypenosides (Gyp, Stevenleaf) induce apoptosis in human hepatoma cells through the up-regulation of Bax and Bak, and down-regulation of Bcl-2, release of mitochondrial cytochrome c and activation of caspase cascade.
2. Gypenosides induce ER stress and production of reactive oxygen species and Ca 2+ , change the ratio of Bcl-2 and Bax, followed by the dysfunction of mitochondria, cause cytochrome c release, activation of caspase-3 before leading to apoptosis, these results provide information towards an understanding of the mechanisms by which Gyp induces cell cycle arrest and apoptosis in human tongue cancer cells.
3. Gypenosides can inhibit invasion and migration of human tongue SCC4 cells by down-regulating proteins associated with these processes, resulting in reduced metastasis.
4. Gypenosides imply their remarkable preventative and therapeutic potential in treatment of neurological diseases involving glutamate and oxidative stress.
5. The extensive antioxidant effect of gypenosides may be valuable to the prevention and treatment of various diseases such as atherosclerosis, liver disease and inflammation.
1. Norisoboldine has been previously implicated to be able to ameliorate the synovial inflammation and abnormal immune conditions in collagen-induced arthritis of mice; it inhibits the macrophage activation and the resultant production of pro-inflammatory cytokines via down-regulating the activation of MAPKs signaling pathways rather than NF-κB.
2. Norisoboldine can alleviate joint destruction in AIA rats by reducing RANKL, IL-6, PGE2, and MMP-13 expression via the p38/ERK/AKT/AP-1 pathway.
3. Norisoboldine attenuates inflammatory pain and decreases forskolin-evoked cyclic adenosine monophosphate levels in mouse spinal cord neuronal cultures through the adenosine A1 receptor.
4. Norisoboldine inhibit VEGF-induced endothelial cell migration via a cAMP-PKA-NF- κB/Notch1 signaling pathway.
1. Silymarin has antioxidant,free radical scavenging activities.
2. Silymarin has hepatoprotective(antihepatotoxic) properties that protect liver cells against toxins.
3. Silymarin has protective effect against UV irradiation-induced apoptosis in human malignant melanoma cells.
4. Silymarin has a beneficial treatment in type II diabetic patients, may via reducing the lipoperoxidation of cell membranes and insulin resistance,significantly decreasing endogenous insulin overproduction and the need for exogenous insulin administration.
5. Silymarin has anti-cancer effects in vitro against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.